Dr. Fatima Cardoso discusses two potentially practice-changing studies, focusing on advanced breast cancer treatments and their implications for clinical practice.
00:41 - PATINA study: Discusses the continuation of anti-HER2 blockade and endocrine therapy versus adding palbociclib
01:29 - EMBER-3 study: Covers the study on ER-positive HER2-negative metastatic breast cancer, comparing oral SERD with standard care and the addition of abemaciclib
02:41 - Raises questions about using CDK4/6 inhibitors after another CDK4/6 inhibitor and the potential of oral SERD for patients with ESR1 mutation